The U.S. Food and Drug Administration said on Tuesday it approved Australian drugmaker Clinuvel Pharmaceuticals Ltd’s treatment for a rare inherited disorder that results in skin damage from exposure to light. The treatment, Scenesse, is an under-the-skin implant that treats erythropoietic protoporphyria, a painful disorder that causes the skin to itch, burn, and scar in some rare cases, when exposed to sunlight and some types of artificial light. It is the company’s only approved treatment and brought in 25.8 million Australian dollars ($17.41 million) in 2018. …read more
Source:: Yahoo Finance
